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Aims Vascular calcification is a recognized predictor of cardiovascular risk in the diabetic patient, with DNA dam-
age and accelerated senescence linked to oxidative stress-associated pathological calcification. Having previ-
ously shown that systemic SIRT1 is reduced in diabetes, the aim was to establish whether SIRT1 is protective




Immunohistochemistry revealed decreased SIRT1 and increased DNA damage marker expression in diabetic calci-
fied arteries compared to non-diabetic and non-calcified controls, strengthened by findings that vSMCs isolated
from diabetic patients show elevated DNA damage and senescence, assessed by the Comet assay and telomere
length. Hyperglycaemic conditions were used and induced DNA damage and enhanced senescence in vSMCs
in vitro. Using H2O2 as a model of oxidative stress-induced DNA damage, pharmacological activation of SIRT1 re-
duced H2O2 DNA damage-induced calcification, prevented not only DNA damage, as shown by reduced comet tail
length, but also decreased yH2AX foci formation, and attenuated calcification. While Ataxia Telanglectasia Mutated
(ATM) expression was reduced following DNA damage, in contrast, SIRT1 activation significantly increased ATM
expression, phosphorylating both MRE11 and NBS1, thus allowing formation of the MRN complex and increasing
activation of the DNA repair pathway.
Conclusion DNA damage-induced calcification is accelerated within a diabetic environment and can be attenuated in vitro by
SIRT1 activation. This occurs through enhancement of the MRN repair complex within vSMCs and has therapeutic
potential within the diabetic patient.
Keywords Vascular calcification • SIRT1 • DNA damage • Diabetes • Senescence
1. Introduction
The prevalence of diabetes is a growing global epidemic, with almost 9%
of the population affected.1 Diabetes is associated with elevated oxida-
tive stress, arising from hyperglycaemia through the activation of the pol-
yol pathway,2 due to poor patient glycaemic control3 and resulting in
increased cardiovascular risk. One of the key comorbidities associated
with diabetes is vascular calcification,4,5 a major cause of mortality within
the western world, in which lipoprotein and calcium accumulate within
the blood vessels, leading to the formation of fatty streak lesions and
mineralized matrix deposition.6 At a molecular level, advanced vascular
calcification is associated with cellular senescence,7,8 telomere erosion
and persistent DNA damage9,10 in response to various cellular stresses
including hyperglycaemia and reactive oxygen species production, fur-
ther promoting the development of calcified matrix deposition within
the vessel. However, the mechanism by which glycaemic conditions ef-
fect DNA damage and the cellular pathways underpinning this is still
unclear.
The DNA damage response (DDR) is a collection of canonical path-
ways, which, following a stress factor, stimulate a variety of sensor pro-
teins including MRE11 RAD50, NBS1 (MRN complex),11 and the histone
variant H2AX.12 The MRN complex has been implicated in several
aspects of DNA double-strand breaks, from initial detection, to trigger-
ing DDR signalling pathways and facilitating repair.13 Considered to be a
flexible scaffold, the MRN complex binds to the break, bridging the bro-
ken DNA, before activating the checkpoint signalling pathway.14 These
sensors are then phosphorylated via recruited transducer proteins such
as Ataxia Telanglectasia Mutated (ATM) to the site of damage,15 leading
to the activation of effector molecules such as checkpoint kinases and ul-
timately p53, which contribute to an arrest in the cell cycle, followed by
DNA repair or apoptosis. Furthermore, H2AX is phosphorylated by
these recruited kinases at the site of DNA damage, leading to increased
recruitment of DDR machinery.6
Sirtuin 1 (SIRT1) is a NADþ dependent deacetylase, with roles in lon-
gevity, ageing, glucose metabolism, and calcification.16,17 This lab and
others have previously reported that a reduction of SIRT1 leads to in-
creased smooth muscle calcification,18,19 and these data suggest it could
be via the osteogenic transcription factor pathway, Runx2. However,
the mechanisms linking the loss of SIRT1 with increased DNA damage
and prevalence of calcification have yet to be elucidated.20,21 SIRT1
deacetylase targets a variety of transcription factors, including the tu-
mour suppressor protein p53,22 tightly regulating its activation with pro-
tection against the DDR pathway by promoting cell survival and
suppressing apoptosis.23 Additionally, a functional link has been shown
between SIRT1 and a member of the double-strand DNA break repair
complex, NBS1, in increasing the resistance to DNA damage,24 but
whether loss of SIRT1 and subsequent NBS1 activation contributes to
diabetes-associated DNA damage has yet to be confirmed. SIRT1 activa-
tors, specifically SRT1720, has been shown to operate as a possible ther-
apeutic for type II diabetes models,25 and has been found to increase
phosphorylated ATM in DNA damage models, reducing the lag time in
the initiation of DNA repair.26
Within the blood, hyperglycaemia, considered a defining trait of diabe-
tes, decreases the reduction of NADPH to NADþ, limiting the amount
of NADþ substrate available to SIRT1, reducing its activation and subse-
quent phosphorylation of the MRN complex.27,28 In turn, this leads to an
increase in hyperglycaemic-induced DNA breaks, and a lack of their
repair, due to the decrease in active MRN complex, thus making SIRT1
activation an attractive target for DNA damage repair. Based on previous
data showing attenuation of vascular calcification following the activation
of the SIRT1 pathway in vitro,19 the aim of this study was to establish of
the links between SIRT1, DNA damage and subsequent vascular cell
calcification.
With previous work demonstrating the significant loss of SIRT1 within
the diabetic patient,19,29 two key questions remain; could activation of
the DDR be linked to lower SIRT1 expression previously been reported
in patients with diabetes and secondly, could modulation of the DDR un-
derpin DNA damage-induced calcification that occurs in diabetes?
2. Methods
2.1 Histological staining
Popliteal arteries harvested from patients with (diabetes mellitus, DM)
and without (non-DM) diabetes undergoing lower limb amputation
were used for histochemical analysis. A panel of internal mammary ar-
tery (IMA) sections were used as non-calcified, non-atherosclerotic con-
trols. Tissue was collected with informed consent under Ethics
Reference 14/NW/1062 and the study was performed in accordance to
the Declaration of Helsinki. Patient details including age, sex, and degree
of atherosclerosis are included in Supplementary material online, Table S1.
Arterial sections were immunolabelled with antibodies as previously
described30, Supplementary material online, Table S2. A TUNEL as-
say (Promega) was used as per manufacturer’s instructions. Sudan
black B lipofuscin staining was used as previously described.31 All
sections were counterstained with nuclear fast red and imaged using
a Zeiss AxioVert microscope. Quantification of p21, c-H2AX, ATM,
MRE11, RAD50, and NBS1 was achieved using colour devolution on
ImageJ32; five fields of view (FoV) were quantified per patient sample
for each stain. Arterial plaques were graded according to the Oxford
grading system.33
2.2 Cell culture
Human vascular smooth muscle cells (vSMCs) were also harvested
from the patient popliteal arterial samples. Non-diabetic primary
human coronary artery vSMCs were purchased from Caltag, UK. All
vSMCs were cultured in smooth muscle cell (SMC) Basal Media 2
(PromoCell), until 80% confluent, then transferred to either; DMEM
containing 5 mM glucose (control conditions; Ctrl), DMEM 5 mM glu-
cose, supplemented with 5 mM b-glycerophosphate (bGP) and
2.6 mM CaCl2 (osteogenic conditions; Ost) or DMEM containing
25 mM glucose supplemented with 5 mM bGP and 2.6 mM CaCl2
[high glucose (HG) conditions, to reflect hyperglycaemic diabetic mi-
lieu]. SIRT1 was modulated via activator SRT1720 (0.5 mM) and SIRT1
inhibitor Sirtinol (10 mM) as previously optimized and described.19
Cells were used between passage 3 and 6.
2.3 Comet assay
A total of 5 105 vSMCs were seeded in 12 well plates in assay depen-
dent conditions for four days. Cells were then treated with 200mM
H2O2 for 30 min, washed in PBS and left to recover in fresh media for 0–
3 h, and the comet assay was conducted as previously described.29 Five
fields of view per slide were taken using a fluorescent microscope (Zeiss
AxioImager Z1) and quantified with CASPLab.
2.4 Reverse transcription and quantitative
polymerase chain reaction
Total RNA was extracted from vSMCs using TriZol (Invitrogen, USA)
and quantified using the Nanodrop2000, (Thermo, USA). qPCR was per-
formed using SYBR Green Lo-ROX (BioLine) using the StepOnePlus
(Thermo, UK). Primers used are detailed in Supplementary material on-
line, Table S3.
2.5 Relative telomere length quantification
Total RNA was extracted from DM vSMCs and controls as described
above was examined for telomere length. In brief, qPCR was conducted us-
ing Tel O primers to amplify the CG rich telomere sequence and normal-
ized against single copy genes (Col6a and Col3a). Initial denaturation was
carried out at 95C for 10 min, followed by 40 cycles of 95C for 60 s,
annealing at 58C for 30 s, and extension at 72C for 30 s. qPCR was per-
formed using SYBR Green Lo-ROX (Bioline) using the StepOnePlus
(Thermo, UK).
2.6 Western blot analysis
Western blot analysis was performed as previously described34 on
whole cell lysates or cell fractions which were isolated using a Nuclear
Extraction Kit (Abcam) and quantified via a BCA assay (Thermo, UK). A
20mg protein extracts were separated on NuPAGE Bis-Tris Gels
(Invitrogen, UK), transferred to a PVDF membrane, blocked, and probed
with antibodies, Supplementary material online, Table S2. Densitometry
was performed using ImageLab software (BioRad) with all samples nor-
malized to a-tubulin.
2.7 Immunofluorescence
vSMCs were seeded in eight well-chamber slides, treated for 4 days be-
fore fixing with paraformaldehyde (4%) for 15 min at room temperature.
Cells were blocked and permeabilized with Tween-20 (1%) in 5% goat
serum in PBS and stained with antibodies, Supplementary material on-
line, Table S2. Slides were mounted with DAPI anti-fade gold (Life
Technologies, UK) and imaged using a fluorescent microscope (Zeiss
AxioImager Z1). Images were quantified using ImageJ software.
2.8 Alizarin red staining
vSMC calcification was determined using Alizarin red S staining. Cells
were cultured for 7 days in calcifying media, with or without the constant
presence of 200mM H2O2 and or 0.5mM SRT1720, before being washed
with PBS prior to fixing with paraformaldehyde (4%) for 15 minutes.
Cells were then washed with PBS before incubating with 2% Alizarin red
in PBS for 10 minutes. Before washing again with PBS and imaging under
a light microscope. Positive staining observed in red.
2.9 Alkaline phosphatase activity
Alkaline phosphatase (ALP) activity was assessed using the p-nitrophenol
phosphate (pNPP) assay. In brief, cells were cultured for 4 and 7 days in
calcifying media with or without SRT1720 activator. Cells undergoing
DNA damage were then treated with 200mM H2O2 for 30 minutes prior
to harvesting and all cells were lysed with 0.05% Triton-X and quantified
using a BCA kit as described above. Enzymatic activity was determined
using 10 M pNPP, read at 410 nm spectrophotometrically, then normal-
ized to total protein concentration and expressed as nmol of nitrophe-
nol formed per mg of cellular protein per minute.
2.10 Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed using a
SimpleChIP enzymatic chromatin IP kit (Cell Signalling Technologies,
USA) as previously described.35 In brief, sheared chromatin was isolated
from day 4-treated vSMCs using an anti-acetyl-lysine antibody (AbCam).
PCR was then performed with primers designed for ATM, RAD50,
MRE11 and NBN promotor regions, Supplementary material online,
Table S3. Fold enrichment was determined via the anti-acetyl-lysine im-
munoprecipitation compared to the 2% input sample, using the compar-
ative Ct method. Amplification compared to negative control was
calculated to confirm specific binding, Supplementary material online,
Figure S1.
2.11 Statistical analysis
All experiments were performed a minimum of four times using inde-
pendent populations of cells and data are presented as the mean ±
SEM. Shapiro–Wilk normality test was used to assess normality.
Analysis of variance was performed with the relevant post hoc tests for
normally distributed data, and Mann–Whitney U test, where data were
not normally distributed, both using Prism 5 software (GraphPad
Software, USA).
3. Results
3.1 Diabetic patients exhibit cellular DNA
damage and decreased tissue expression of
SIRT1
Vessels taken from DM and non-DM patients undergoing lower limb am-
putation were examined histologically for calcification, senescence and
DNA damage markers. Von Kossa staining positively identified calcifica-
tion in both DM and non-DM arterial samples, with an absence of SIRT1
staining within the vessel wall on the DM sections, while positive SIRT1
staining was evident in the non-DM patient vessel (Figure 1). Senescence
markers, Sudan Black and p21 staining confirmed the presence of senes-
cence located within the smooth muscle layer of the DM vessel, with
less staining in non-DM vessels. Furthermore, the TUNEL assay and c-
H2AX staining demonstrated the presence of double-stranded breaks
(DSBs) in DM vessels, which was less apparent in non-DM vessels
(Figure 1A). The number of p21-positive foci and c-H2AX staining was
quantified using ImageJ in both DM, non-DM (Figure 1) and IMA
(Supplementary material online, Figure S2) arterial sections. A significantly
higher number of p21 foci were detected in DM vessels compared to
both non-DM (P = 0.015) and IMA vessels (P = 0.0020). Furthermore,
significantly less p21 foci were observed in IMA compared to non-DM
vessels (P = 0.030) (Figure 1B). c-H2AX was also quantified within the tis-
sue. DM vessels exhibited significantly greater levels of c-H2AX com-
pared to both DM (P < 0.0010) and non-DM vessels (P < 0.0010)
(Figure 1C).
Given the apparent localization of these DNA damage markers within
the medial layer of the vessel wall, it was next of interest to establish
whether DNA damage was increased in vSMCs isolated from patients
with diabetes compared to non-DM cells and if this inversely correlated
with SIRT1 expression. Therefore, known markers of DNA damage
were analysed in an in vitro cell culture model. vSMCs harvested from
DM calcified popliteal vessels demonstrated an increased level of persis-
tent DNA damage compared to healthy vSMC controls, indicated by a
significantly greater comet tail percentage (P < 0.0010) and tail moment
(P < 0.0010) (Figure 2A) compared to non-calcified controls. Telomere
length was also significantly decreased four-fold in DM vSMCs compared
to healthy controls (P = 0.0095) (Figure 2B). Conversely, markers of se-
nescence, p21 and p53 mRNA abundance was increased in DM patients,
compared to healthy controls (P = 0.0022), (P = 0.048), respectively
(Figure 2C and D). ATM, a protein known to phosphorylate c-H2AX fol-
lowing DNA breaks, was up-regulated three-fold in DM vSMCs com-
pared to healthy controls at the mRNA level (P = 0.048) (Figure 2E).
SIRT1 expression was significantly decreased in diabetic vSMCs at both
the mRNA (P = 0.0020) (Figure 2F) and protein level (P = 0.0022)
(Figure 2G), corroborating the immunohistochemical data (Figure 1A) and
supporting previous systemic findings in diabetic patients.19
3.2 Hyperglycaemic conditions induce
DNA damage
Phosphorylation of histone H2AX at Ser139 is considered to be an early
marker of DNA damage and correlates with the development of
DSBs.36 To determine how a diabetic environment modulates DNA
damage in vSMCs, and if this could be linked to calcification, a
well-established in vitro calcification model30 was utilized, modified to in-
corporate diabetic conditions. Cells were cultured in either a healthy
physiologically relevant concentration of 5 mM glucose37 (Control; Ctrl),
or 5 mM glucose with the addition of CaCl2 and bGP (Osteogenic; Ost),
or finally, 25 mM glucose and osteogenic conditions (High glucose; HG),
comparable to a DM patient during a moderate hyperglycaemic attack.38
Control cells exhibited a baseline of 12 c-H2AX foci per cell, with many
cells exhibiting no foci at all (Figure 3A). However, when cultured in HG,
cells exhibited significantly more foci when compared to both control
(P = 0.0072) and osteogenic (P = 0.0079) conditions.
The tumour suppressor protein, p53, has previously been
reported to mediate cell cycle arrest in HG conditions19 and its
expression further activates downstream senescence marker p21,
therefore p21 foci were next examined. There was no apparent
difference in the number of p21 foci detected between osteogenic
conditions compared to control conditions (Figure 3B), however, it
is of note that in the presence of the HG conditions p21 foci
were significantly increased compared to control (P = 0.033). A
comet assay was used to determine naturally occurring DSBs in
the in vitro model. Tail moment was significantly increased in HG
conditions compared to both osteogenic (P < 0.0001) and control
conditions (P < 0.0001) and furthermore, a two-fold increase was ob-
served in tail percentage between both control and osteogenic and
HG conditions (Figure 3C). Finally, total c-H2AX protein expression
harvested at Day 4 was assessed via western blotting, with a signifi-
cant increase detected in HG conditions compared to both osteo-
genic (P = 0.0003) and control conditions (P < 0.0001) (Figure 3D).
3.3 SIRT1 attenuates DNA damage-
induced vSMC osteogenic differentiation
Given the loss of SIRT1 within a diabetic environment, and having shown
that HG conditions induce DNA damage (Figure 3), it was next of interest
to determine whether restoration of SIRT1 could rescue the DNA dam-
age and its calcification effects. vSMCs were cultured in the three growth
Figure 1 Vessels isolated from patients with diabetes exhibit DNA damage and low SIRT1 expression. Representative micrographs of popliteal 
arteries harvested from diabetic patients (DM) and non-diabetic patients (non-DM) undergoing lower limb amputation. (A) DM and non-DM patient 
vessels were stained; for von Kossa, indicated by silver phosphate ion accumulation (n = 5), SIRT1 (n = 5), senescence markers lipofuscin (Sudan B) (DM n 
= 4,  non-DM  n = 5),  p21  (n = 5). TUNEL assay, demonstrating double stranded DNA nicks (n = 5)  and  c-H2AX (n = 5).  Scale  bar =  200lm. (B) 
Quantified p21 foci number in DM, non-DM and control internal mammary artery (IMA) vessels (n = 5 patients per group; 5 FoV per patient) and 






.conditions in the presence or absence of H2O2 and SIRT1 activator,
SRT1720. Cells exposed to elevated oxidative stress by treatment with
H2O2 for 7 days exhibited no significant change in the control conditions;
however, there was a significant increase in calcification in osteogenic
(P = 0.043) and HG (P = 0.047) conditions compared to the same condi-
tions without H2O2 treatment (Figure 4A). Furthermore, the addition of
SRT1720 to H2O2 treated cells reduced alizarin red staining by half in
both osteogenic (P = 0.042) and HG (P = 0.047) conditions (Figure 4A).
Figure 2 Diabetic patient vSMCs exhibit DNA damage and low SIRT1 expression. (A) Double stranded DNA breaks were assessed via the comet as-
say in control (n = 6) and diabetic (DM) (n = 6) vSMCs. Tail moment and tail DNA percentage were calculated via CASPLab. Scale bar = 20lm. (B)
Telomere length of control (n = 6) and DM (n = 6) vSMCs was quantified via qPCR and normalised to Col3a1 and Col6a1. (C) p21 (n = 6) (D) p53, (n = 6)
(E) ATM (n = 6) and (F) SIRT1 (n = 6) mRNA expression from DM vSMCs was compared to controls via qPCR. (G) SIRT1 protein expression within DM
and control vSMCs was assessed by western blot analysis and normalized to a-tubulin (n = 6). A Mann–Whitney U test was performed. *P < 0.05,
**P < 0.01, ***P < 0.001.
ALP activity; an early marker of osteogenic differentiation, was
increased on Day 4 in osteogenic (P = 0.0029) conditions as expected
and this effect was enhanced in HG conditions compared to control
(P = 0.0002). Furthermore, in the presence of H2O2 treatment, ALP ac-
tivity was increased in HG compared to both control (P = 0.0004) and
osteogenic (P = 0.011) conditions. However, when treated with
SRT1720 to restore SIRT1 levels, the H2O2-induced ALP activity was
prevented in HG conditions (P < 0.0001) (Figure 4B), supporting the
Alizarin red data shown in Figure 4A.
To confirm the development of osteogenic differentiation, Runx2 and
OCN mRNA abundance was examined following 4 days of treatment.
Both Runx2 (Figure 4C) and OCN (Figure 4D) were elevated in untreated
HG conditions compared to control (P = 0.019) and (P < 0.0001) respec-
tively, with a further significant increase under HG conditions when cells
were treated with H2O2 (P = 0.0059) and (P = 0.029), respectively.
SIRT1 activation reduced both Runx2 (P < 0.0001) and OCN
(P = 0.0009) mRNA levels in HG conditions. Given the observed
increase in osteogenic markers following H2O2, the effect of H2O2 on
SIRT1 expression was assessed. Following 4 days of H2O2 treatment in
HG conditions, SIRT1 was significantly reduced compared to control
(P = 0.0010), however following H2O2 treatment, SIRT1 expression was
increased in all three conditions, with a significant up-regulation detected
between the two HG conditions (P = 0.0079) (Figure 4E). To further
identify the regulation and cellular translocation of SIRT1 following
H2O2 treatment, its subcellular localization was determined using frac-
tionation studies. In untreated conditions, there was an even distribution
of SIRT1 between the cytoplasm and the nucleus. However, when
treated with H2O2 under HG conditions, SIRT1 was retained almost
Figure 3 Hyperglycaemic conditions increase DNA damage in vitro. The effect of osteogenic (Ost) and hyperglycaemic (HG) conditions in a vSMC
model was assessed. (A) c-H2AX foci (n = 5) and (B) p21 foci (n = 8) were examined via fluorescent staining (green) and quantified using ImageJ, with rep-
resentative images shown. Scale bar = 20lm. (C) DSBs were confirmed via the comet assay and quantified via CASPLab (n = 6). (D) c-H2AX expression
was assessed in protein harvested from all three treatments via western blot analysis and normalized to a-tubulin (n = 10), with representative images
shown. A one-way ANOVA followed by a Tukey post hoc test was performed. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 4 SIRT1 activation inhibits DNA damage-induced osteogenic differentiation. Thirty minutes of 200mM H2O2 treatment induces osteogenic
vSMC differentiation through the Runx2 pathway. (A) Alizarin red staining was assessed at Day 7 following constant treatment with H2O2 for 7 days and
quantified colorimetrically (n = 4). (B) ALP activity was assessed at Day 4 via the p-nitrophenol phosphate assay (n = 5). (C) Runx2 (n = 5) and (D) OCN
(n = 5) mRNA expression was assessed via qPCR. (E) SIRT1 protein levels were determined in total protein isolated from untreated and H2O2-treated
cells via western blot analysis and normalised to a-tubulin (n = 4). (F) Protein was fractionated and nuclear and cytoplasmic SIRT1 levels assessed via west-
ern blot analysis and normalized to histone H3 and a-tubulin, respectively (n = 4). A one-way ANOVA followed by a Tukey post hoc test was performed.
*P < 0.05, **P < 0.01, ***P < 0.001.
Figure 5 SIRT1 activation decreases DNA damage. c-H2AX expression was confirmed via fluorescent staining. Cells were pre-treated with SRT1720
(SIRT1 activator) or Sirtinol (SIRT1 inhibitor) for 4 days prior to 30 min H2O2 treatment and left to recover for up to 3 h before (A) staining for c-H2AX
(green) and with DAPI (blue) (n = 4) or (B) undergoing the comet assay to confirm DSBs. (n = 6). A two-way ANOVA followed by a Tukey post hoc test
was performed. *P < 0.05, **P < 0.01, ***P < 0.001.
entirely to the cytoplasm, instead of being translocated to the nucleus
(P = 0.0005) as occurred in untreated conditions (Figure 4F).
3.4 SIRT1 activation protects against DNA
damage
Having demonstrated the loss of SIRT1 correlates with an increase in
DNA damage, the effect of SIRT1 modulation was examined in vSMCs
following recovery from DSBs induced by H2O2. vSMCs were treated
for 4 days with SIRT1 activator, SRT1720, or a SIRT1 inhibitor, Sirtinol,
before either staining and counting c-H2AX foci within the nucleus or
undergoing single-cell electrophoresis. Cells were either left untreated
or treated with 200mM H2O2 for 30 min, then left to recover in fresh
media before staining at 1 h and 3 h time points. c-H2AX staining was
significantly increased at 3 h following damage within control conditions
with the addition of Sirtinol (P = 0.028), and significantly decreased by
the addition of SRT1720 (P = 0.015) (Figure 5A). Similarly, within the os-
teogenic conditions, cells treated with Sirtinol exhibited significantly
more c-H2AX foci compared to SRT1720 treatment (P = 0.0088).
Within the HG treated cells, a significant increase was observed in c-
H2AX at 1 h following treatment between SIRT1 activated and inhibited
cells (P = 0.015). Following 3 h recovery, SRT1720 reduced foci count by
over half compared to Sirtinol treatment (P < 0.0001), with SRT1720-
treated cells expressing 40% less foci than untreated conditions
(P = 0.0039). Sirtinol increased foci accumulation by over 20% compared
to untreated conditions (P = 0.0037) (Figure 5A).
DSBs were again assessed using the comet assay. Following pre-
treatment for 4 days with SIRT1 activator, SRT1720, or SIRT1 inhibitor,
Figure 6 DNA damage markers ATM and the MRN complex are present in diabetic patient vessels. (A) Representative micrographs of popliteal arter-
ies harvested from diabetic (DM) and non-diabetic (non-DM) patients undergoing lower limb amputation and stained for ATM, MRE11, RAD50 and
NBS1 (n = 5). Scale bar = 200lm. (B) Positive black foci number was calculated via ImageJ for ATM, MRE11, RAD50, and NBS1 in diabetic (DM), non-dia-
betic (non-DM), and control internal mammary artery (IMA) vessels (n = 5 patients per group; 5 FoV per patient). A one-way ANOVA followed by a
Tukey post hoc test was performed. *P < 0.05, **P < 0.01, ***P < 0.001.
Sirtinol, cells were either left untreated or treated with 200mM of H2O2
for 30 min and left to recover in fresh media before DNA was isolated
and assessed to determine DNA damage (Figure 5B). Tail moment, an in-
dex of induced DNA damage, taking into consideration both migration
and relative amount of DNA in the tail, was also used to assess the DNA
damage and subsequent repair. Within controls, tail moment did not
vary significantly between 0 h and 3 h after damage, however, a significant
increase was identified between Sirtinol (P < 0.0001) and untreated
(P < 0.0001) cells, compared to SRT1720 treatment. Within osteogenic
conditions, SIRT1 inhibition increased tail moment over five times com-
pared to control (P < 0.0001) and SRT1720 treatment (P < 0.0001), with
SIRT1 activation reducing tail moment compared to untreated controls
Figure 7 SIRT1 activation reduces activation of the MRN complex. (A) Expression of ATM (n = 4), p-MRE11 (n = 5), MRE11 (n = 5), RAD50 (n = 5), p-
NBS1 (n = 5), and NBS1 (n = 5) was assessed within the vSMC calcification model in control (C), osteogenic (O) and high glucose (H) conditions in the
absence (unt) or presence of DNA damage (H2O2) and SIRT1 activator (SRT), via western blot analysis and normalized to a-tubulin, with representative
images shown. (B) Chromatin immunoprecipitation was performed with an anti-acetyl-lysine antibody to assess the acetylation profile of the promotor
regions of ATM and MRN complex with the vSMC model (n = 3). A one-way ANOVA followed by a Tukey post hoc test was performed. *P < 0.05,
**P < 0.01, ***P < 0.001.
(P < 0.0001). Under HG conditions, SIRT1 activation significantly re-
duced tail moment compared to untreated (P < 0.0001) and Sirtinol
treated (P < 0.0001).
Tail percentage was increased 1 h after damage in Sirtinol-treated con-
trol conditions compared to both untreated control (P < 0.0001) and
SRT1720 treated conditions (P < 0.0001). Furthermore, following a 3 h
recovery a significant increase was observed in untreated compared to
SRT1720 treated cells (P = 0.0014), with a greater increase detected in
Sirtinol control conditions compared to both untreated (P < 0.0001) and
SRT1720 (P < 0.0001). Within osteogenic conditions, Sirtinol treatment
significantly increased tail percentage by 40% compared to SRT1720
conditions (P = 0.0046), with no difference observed between untreated
and SRT1720. However, following a 3 h recovery, SRT1720 reduced tail
percentage by over 10%, significantly less than both untreated
(P < 0.0001) and Sirtinol-treated (P < 0.0001). Sirtinol inhibition of SIRT1
increased tail percentage by four-fold compared to untreated
(P < 0.0001). Finally, a significant increase in tail DNA percentage was ob-
served in Sirtinol HG conditions compared to control after 1 h
(P < 0.0001), which was sustained during the 3 h recovery period
(P < 0.0001). A significant reduction was observed following SRT1720
pre-treatment compared to both untreated (P < 0.0001) and Sirtinol-
treated cells (P < 0.0001).
3.5 SIRT1 activation reduces chromatin
acetylation and increases MRN activation
When DNA damage occurs within the nucleus, the cell responds by
recruiting sensor proteins to the damage sites which orchestrate the for-
mation of multiprotein complexes for DDR activation.39 Initially H2AX
is bound to DSBs, where it binds and is phosphorylated via an active
acetylated ATM. This phosphorylation binds NBS1 first, forming a tri-
meric complex with MRE11 and RAD50, tethering the MRN complex to
the DNA damage site before translocating to the nucleus and forming
distinct foci with c-H2AX at DSBs.13
Calcified vessels from DM and non-DM patients were assessed for
the presence of ATM and the MRN complex using immunohistochemis-
try. Positive staining confirmed the presence of ATM, RAD50 MRE11
and NBS1 within the vSMC layer of DM vessels, which was present to a
lesser extent in non-DM vessels (Figure 6A) and absent in control, non-
calcified, non-atherosclerotic IMA (Supplementary material online, Figure
S2). Foci number for ATM, RAD50, MRE11 and NBS1 was quantified us-
ing ImageJ. ATM foci number was significantly greater in DM vessels
compared to both non-DM (P = 0.012) and IMA (P < 0.0001), with non-
DM vessels exhibiting significantly greater numbers of ATM foci than
IMA (P = 0.039). Secondly, MRE11 foci number was significantly greater
in DM compared to non-DM (P = 0.0002) and IMA tissue (P = 0.0008)
and also in non-DM compared to IMA (P = 0.0023). The number of
RAD50 foci was significantly greater in DM vessels compared to both
non-DM (P = 0.0011) and IMA (P = 0.0004), with non-DM vessels exhib-
iting significantly greater numbers of RAD50 foci than IMA (P = 0.0033)
(Figure 6B). NBS1 foci number was significantly increased in DM vessels
compared to non-DM (P = 0.015) and IMA (P = 0.0002), with non-DM
significantly increased compared to IMA (P = 0.043).
Since DDR activation is primarily activated by the protein ATM phos-
phorylating downstream effector proteins,40 its activation profile was
considered. Total ATM protein expression was increased in HG com-
pared to control conditions (P = 0.043) (Figure 7A). H2O2-treated cells
induced significantly less ATM than H2O2 with SRT1720 (P = 0.040),
with SRT1720 activation increasing ATM expression significantly
compared to untreated HG conditions (P = 0.0008). Activation of the
MRN complex was next examined. Phosphorylation of MRE11 was sig-
nificantly increased following SIRT1 activation compared to untreated
(P = 0.0010) and H2O2 alone (P < 0.0001), with no significant change
detected between untreated and H2O2 damage in all three conditions.
Total RAD50 protein expression was significantly elevated following HG
H2O2 treatment (P = 0.0010) compared to untreated HG conditions.
Moreover, a further up-regulation was observed following SIRT1 activa-
tion (P < 0.0001). Finally, no change was found in NBS1 phosphorylation
following H2O2 treatment, however, a significant increase was observed
under HG conditions with SIRT1 activation, compared to untreated HG
(P = 0.0015) and H2O2 alone (P = 0.0002).
Secondly, ChIP qPCR was performed to determine the acetylation
profile of the promotor region within the ATM gene. Acetylation was
significantly increased in the HG environment compared to osteogenic
conditions (P = 0.0054), with SIRT1 activation significantly reducing the
acetylation around the H3K27Ac marks (P = 0.0074) (Figure 7B).
Acetylation of the MRE11 promotor region was reduced under osteo-
genic and HG conditions, correlating with an increase in total MRE11
production. RAD50 promotor acetylation was significantly increased fol-
lowing HG treatment compared to control (P = 0.0019) and osteogenic
conditions (P = 0.0010), with SIRT1 activation significantly reducing acet-
ylation (P = 0.0012). NBS1 promotor acetylation was significantly in-
creased following HG treatment (P = 0.0002) and reduced following
SIRT1 activation (P = 0.0002) (Figure 7B).
4. Discussion
Previously, SIRT1 has been identified as a longevity gene and was
shown to be down-regulated within diabetic patients,19,41 while up-
regulation of SIRT1 has been reported to slow a range of degenera-
tive diseases via regulation of energy balance and protection against
cellular senescence and apoptosis.29,42 Vascular calcification, a highly
prevalent pathology and a serious comorbidity of diabetes, is associ-
ated with major cardiovascular events, in which vascular smooth
muscle cells play an integral role in mediating the development of cal-
cification via osteogenic differentiation and the release of vesicles that
deposit calcium-phosphate hydroxyapatite crystals along the matrix.
Whilst previous studies have focused on the development of DNA
damage within atherosclerotic plaques, this is the first in vitro study to
demonstrate that DNA damage-activated osteogenic differentiation in
smooth muscle cells may be perpetuated via a loss of SIRT1.
Furthermore, this study demonstrates that restoring SIRT1 levels,
may further activate the MRN DNA repair complex and return cells
to their normal quiescent state, thereby preventing subsequent dam-
age due to senescence and apoptosis.
This study clearly establishes an increased presence of DNA damage
markers in calcified popliteal vessels from patients with diabetes com-
pared to those without. This strengthens previously published data dem-
onstrating reduced SIRT1 within diabetic serum compared to healthy
controls.19 The findings within this study demonstrate a link between the
loss of SIRT1 and increased DNA damage in patients with diabetes.
Additionally, senescence markers, Sudan Black, p21 and the TUNEL as-
say suggest that the development of calcification correlates with in-
creased DNA damage in areas which lack SIRT1. The expression of
SIRT1 was reduced in diabetic vSMCs compared to healthy controls,
with a significant up-regulation of p53, p21 and a decrease in telomere
length, suggesting that an integral part of the diabetic vSMC phenotype is
the development of a senescent state and an increase in DNA damage,
in agreement with previous findings.43,44 Interestingly, ATM expression
was up-regulated in diabetic vSMCs, implicating that whilst DNA damage
is increased in diabetic cells, the response mechanism may be inhibited
further downstream within this pathway, thus, unable to prevent
senescence.
To further investigate the mechanistic pathways involved, a human
coronary artery cell model was used, where vSMCs were cultured under
osteogenic conditions in the presence or absence of high glucose, with
or without H2O2 to induce DNA damage and also in the presence of ei-
ther a SIRT1 activator (SRT1720) or a SIRT1 inhibitor (Sirtinol). HG con-
ditions were found to increase the rate of DNA damage, c-H2AX and
p21 foci numbers and both tail percentage and tail length of comets
compared to controls. Whilst vSMCs within normal vessels are charac-
terized as having low levels of osteogenic marker expression, this study
demonstrated that an increase in osteogenic markers Runx2 and OCN
occurred following DNA damage, with HG conditions exacerbating
their expression. Additionally, ALP activity and Alizarin red staining was
also increased within H2O2 damaged cells. Although SIRT1 has multiple
functions, this is the first study to directly link the increase in SIRT1 activ-
ity to a reduction in DNA damage-induced vascular calcification and os-
teogenic differentiation of vSMCs.
Following DNA damage, SIRT1 expression was increased within
H2O2 damaged cells, and upon further investigation via cell fractionation,
SIRT1 levels were found to be significantly reduced within the nucleus
following DNA damage, with increased SIRT1 expression within the cy-
toplasm compared to control conditions. Whilst previous work has
been conducted on the role of SIRT1 within the nucleus, predominantly
as a nuclear shuttling partner for a variety of transcription factors includ-
ing key senescence regulator p53 and FOXO,45–47 there is still debate
surrounding SIRT1 regulation within the cytoplasm as well as the nucleus
under different metabolic states.48 Previous work in Drosophila has
shown that during embryonic development, dynamic changes occur in
the subcellular localization of Sir2,49 with more recent studies suggesting
that the nucleo-cytoplasmic shuttling of SIRT1, as observed in here and
elsewhere, increases cellular resistance to apoptosis and may increase
participation in cellular differentiation.50,51 Furthermore, this study is the
first to demonstrate a lack of SIRT1 in the nucleus compared to its pres-
ence in the cytoplasm in H2O2 and HG-treated conditions, suggesting a
direct cytoplasmic regulation of SIRT1 within this diabetic environment.
Previous studies have suggested that phosphorylation of SIRT1 at Ser-
16452 may inhibit the nuclear translocation of SIRT1, allowing its reten-
tion in the cytoplasm and overall reduction in activity. Collectively, these
data may offer an explanation as to the lack of improvement observed in
the DDR even though SIRT1 protein levels are increased during H2O2
treatment, due the inability of SIRT1 to interact and promote the activa-
tion of DNA repair pathways53 and further suppress osteogenic
differentiation.19
To further evaluate the role of SIRT1 in H2O2-induced DNA damage,
SIRT1 was inhibited via Sirtinol and activated via SRT1720. The presence
of c-H2AX was confirmed via quantification of foci accumulation in the
nucleus. Inhibition of SIRT1 demonstrated an increase in foci, which ex-
ponentially increased during a 3 h recovery time. Conversely, c-H2AX
staining for cells treated with SRT1720 peaked at 1 h following H2O2
treatment, with a reduction in c-H2AX staining detected after 3 h.
Previous studies have suggested a mechanism in which SIRT1 physically
interacts with acetyl-transferase Tip60, inhibiting the acetylation of c-
H2AX and thus reducing the cellular response, something these data
corroborate.54 Furthermore, SIRT1 knockout cells appear to have
increased sensitivity to radiation damage and are more likely to undergo
cell death than wild-type cells,55 again suggesting that deacetylation of
proteins in this pathway is required to prevent cells from acquiring a se-
nescent or apoptotic phenotype.
DNA damage was also assessed using the comet assay, with SIRT1 ac-
tivation significantly reducing comet length after 3 h, suggesting activation
of a repair pathway, with SIRT1 inhibition having converse effects.
Further examination of the DNA repair pathways demonstrated phos-
phorylation of both NBS1 and MRE11 within SIRT1 activated cells, which
may account for the repair observed in DNA damaged cells following
SIRT1 activation. Previous studies have suggested that following DNA
damage, NBS1 and SIRT1 are both recruited to the chromatin, and asso-
ciated with one another, causing a deacetylation of NBS1, a prerequisite
to its activation.24 This effect is corroborated by these data, with SIRT1
activation reducing acetylation around the H3K27ac mark within the
transcription start site, suggesting that deacetylation promotes produc-
tion of the NBS1 protein, enabling an active MRN repair complex to be
produced. In addition, within HG conditions, acetylation of the NBS1
promotor is significantly increased with no further phosphorylation or
production of NBS1 protein, indicating that whilst HG conditions are suf-
ficient to induce DNA damage, they do not activate the DNA repair
MRN complex, possibly explained by the reduction of SIRT1 within the
cells. These data further confirm that SIRT1 activation is required for the
phosphorylation of MRE11 following DNA damage via the ATM kinase,
which is simultaneously up-regulated via SIRT1 activation. Previous studies
have demonstrated that phosphorylation of MRE11 via ATM at s676 and
s678 is important in the response to DNA DSBs and is dependent on the
activation and presence of NBS1.56 This is consistent with data in this
study, suggesting that both MRE11 and NBS1 should be phosphorylated
to induce repair. Interestingly, RAD50 expression significantly increased
following DNA damage within HG conditions, however, no increase in
DNA repair was observed via the comet assay. This is in line with previous
studies that demonstrate phosphorylation of both MRE11 and NBS1 may
be more critical to MRN activation than RAD50 production.57
In summary, these data suggest a model in which DNA repair through
the MRN complex is not fully activated by a diabetic environment, possi-
bly due to loss of SIRT1 within the patient. Loss of SIRT1 may lead to in-
creased acetylation of NBS1, blocking its phosphorylation sites, thereby
inhibiting further activation of ATM and thus the formation of the MRN
complex, and ultimately DNA repair.28 This work extends previous
studies suggesting that a loss of SIRT1 may be responsible for inducing a
pro-apoptotic, pro-calcification environment in which p53-mediated
DNA repair is inhibited.58,59 These findings add further strength to this
hypothesis, demonstrating that an increase in SIRT1 expression pro-
motes MRN activation, resulting in increased DNA repair and cell sur-
vival. Most importantly, this work highlights the complex regulation
SIRT1 in diabetes, and importance in the role of DNA damage in vascular
calcification. This offers new insights into specific therapeutic targets that
could be used for development with potent SIRT1 analogues in the fu-
ture, thus providing hope into an improved management of diabetic-
associated calcification, a pathology for which there is no current
treatment.
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17. Cantó C, Auwerx J. Targeting SIRT1 to improve metabolism: all you need is
NAD(þ)? Pharmacol Rev 2012;64:166–187.
18. Badi I, Mancinelli L, Polizzotto A, Ferri D, Zeni F, Burba I, Milano G, Brambilla F,
Saccu C, Bianchi ME, Pompilio G, Capogrossi MC, Raucci A. miR-34a promotes vas-
cular smooth muscle cell calcification by downregulating SIRT1 (Sirtuin 1) and Axl
(AXL Receptor Tyrosine Kinase). Arterioscler Thromb Vasc Biol 2018;38:2079–2090.
19. Bartoli-Leonard F, Wilkinson FL, Schiro A, Inglott FS, Alexander MY, Weston R.
Suppression of SIRT1 in diabetic conditions induces osteogenic differentiation of hu-
man vascular smooth muscle cells via RUNX2 signalling. Sci Rep 2019;9:878.
20. Takemura A, Iijima K, Ota H, Son BK, Ito Y, Ogawa S, Eto M, Akishita M, Ouchi Y.
Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle
cells. Arterioscler Thromb Vasc Biol 2011;31:2054–2062.
21. Bartoli-Leonard F, Wilkinson FL, Langford-Smith AWW, Alexander MY, Weston R.
The interplay of SIRT1 and Wnt signaling in vascular calcification. Front Cardiovasc
Med 2018;5:183.
22. Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G, Bremner R. Division and apo-
ptosis in the E2f-deficient retina. Nature 2009;462:925–929.
23. Song S-H, Lee M-O, Lee J-S, Oh J-S, Cho S-U, Cha H-J. Sirt1 promotes DNA damage
repair and cellular survival. Biomol Ther 2011;19:282–287.
24. Yuan Z, Zhang X, Sengupta N, Lane WS, Seto E. SIRT1 regulates the function of the
Nijmegen breakage syndrome protein. Mol Cell 2007;27:149–162.
25. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni
RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek
H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM,
Jirousek MR, Elliott PJ, Westphal CH. Small molecule activators of SIRT1 as thera-
peutics for the treatment of type 2 diabetes. Nature 2007;450:712–716.
26. Guarente L. Overcoming ATM deficiency by activating the NADþ/SIRT1 axis. Cell
Metab 2016;24:526–528.
27. Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev
Cancer 2015;15:608–624.
28. Yuan Z, Seto E. A functional link between SIRT1 deacetylase and NBS1 in DNA dam-
age response. Cell Cycle 2007;6:2869–2871.
29. Gorenne I, Kumar S, Gray K, Figg N, Yu H, Mercer J, Bennett M. Vascular smooth
muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis.
Circulation 2013;127:386–396.
30. Ndip A, Williams A, Jude EB, Serracino-Inglott F, Richardson S, Smyth JV, Boulton AJ,
Alexander MY. The RANKL/RANK/OPG signaling pathway mediates medial arterial
calcification in diabetic Charcot neuroarthropathy. Diabetes 2011;60:2187–2196.
31. Georgakopoulou EA, Tsimaratou K, Evangelou K, Fernandez Marcos PJ, Zoumpourlis
V, Trougakos IP, Kletsas D, Bartek J, Serrano M, Gorgoulis VG. Specific lipofuscin
staining as a novel biomarker to detect replicative and stress-induced senescence. A
method applicable in cryo-preserved and archival tissues. Aging 2012;5:37–50.
32. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image
analysis. Nat Methods 2012;9:671–675.
33. Redgrave J, Lovett J, Gallagher P, Rothwell P. Histological assessment of 526 symp-
tomatic carotid plaques in relation to the nature and timing of ischemic symptoms:
the Oxford Plaque Study. Circulation 2006;113:2320–2328.
34. Liu Y, Wang T, Yan J, Jiagbogu N, Heideman DA, Canfield AE, Alexander MY. HGF/
c-Met signalling promotes Notch3 activation and human vascular smooth muscle cell
osteogenic differentiation in vitro. Atherosclerosis 2011;219:440–447.
35. Pritchett J, Athwal VS, Harvey E, Martin K, Llewellyn J, Ireland P, Nicolaides A,
Humphries MJ, Bobola N, Hanley NA, Piper Hanley K. Epimorphin alters the inhibi-
tory effects of SOX9 on Mmp13 in activated hepatic stellate cells. PLoS One 2014;9:
e100091.
36. Kuo LJ, Yang LX. Gamma-H2AX—a novel biomarker for DNA double-strand breaks.
In Vivo 2008;22:305–309.
37. Danaei G, Finucane M, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F,
Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. National,
regional, and global trends in fasting plasma glucose and diabetes prevalence since
1980: systematic analysis of health examination surveys and epidemiological studies
with 370 country-years and 2.7 million participants. Lancet 2011;378:31–40.
38. Berk J, Wade R, Baser HD, Lado J. Case report: severe reversible cardiomyopathy as-
sociated with systemic inflammatory response syndrome in the setting of diabetic
hyperosmolar hyperglycemic non-ketotic syndrome. BMC Cardiovasc Disord 2015;15:
123.
39. Giglia-Mari G, Zotter A, Vermeulen W. DNA damage response. Cold Spring Harb
Perspect Biol 2011;3:a000745.
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Translational perspective
Our study provides the first evidence that DNA damage is enhanced in the vasculature of the diabetic patient and that this process, in tandem with
loss of SIRT1, exacerbates pathological smooth muscle cell calcification. We propose that current SIRT1 activators and their analogues may be use-
ful as investigational tools, and further elucidation of downstream mechanisms of SIRT1 will aid the development of novel and more precise drug
regimens.
